Novo’s High-Dose Wegovy Gets US Approval in Needed Boost

Novo Nordisk A/S won approval to sell a high-dose version of its blockbuster Wegovy obesity shot in the US, allowing it to offer weight loss closer to Eli Lilly & Co.’s rival Zepbound.

Novo will start selling the medicine in the US in April, the Danish drugmaker said in a statement on Thursday. It will come in the form of a single-dose pen, and will be available through cash-pay and pharmacy channels, the company said. The Food and Drug Administration approval was granted as part of a new US national priority voucher program, which allows for faster-than-normal review of medicines deemed to be aligned with the country’s priorities.